YouScript’s Post

Joanne Babula, Research Scientist at Ridgeline Therapeutics, highlights the transformational impact CDD Vault has on data organization and collaboration: "We were spun out of academia and didn't have any data tracking system. With CDD Vault we are now able to compile all results in one place and compare different compounds on the same page - really useful! The ELN is very beneficial as well. We can easily prepare a slide deck from the well-organized data to present to investors and partners." Ready to organize and showcase your data with ease? Explore CDD Vault today: https://lnkd.in/eAx_GUZT #CDDVault #DataOrganization #ScientificCollaboration #ResearchInnovation #ELN

Friends were asking about research on children allergies. This is exciting!

Are you ready to revolutionize your research? Join us for an exclusive webinar with Revvity!!🧬✨ Discover how RASTRUM’s cutting-edge 3D cell models can accelerate your drug discovery process and deliver more meaningful insights, faster than ever. Don’t miss the chance to see this game-changing technology in action! See details for registration below! Secure your spot now and take the next step in your research journey! 👩🔬👨🔬 #Webinar #3DCellCulture #OncologyResearch #RASTRUM #Inventia

We're excited to announce our strategic partnership with Vipergen ApS to provide DNA encoded library (DEL) screening and integrated drug discovery services. The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a living cell or on a purified drug target protein. Access the full story here! https://lnkd.in/g7s7MhJ8 Commenting on the partnership our CEO, Akhil Ravi said that “The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer centric approach. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us." Nils Jakob Vest Hansen, Ph.D., CEO of Vipergen, added that “we are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers.   #collaboration #partnership #media #drugdiscovery #screening #DNA #encoded #library #innovation #CRDMO #aurigene  

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> It takes GUTS to be BOLD: A look at the new biotech tickers: As the public markets heat up in biotech, industry insiders expect a small drumbeat of IPOs later this spring, and that means a new set of stock tickers to track. Next up is BOLD, the proposed name of Boundless Bio’s Nasdaq stock. Using that name would mark a return for the ticker, which freed up after Astellas bought Audentes Therapeutics for $3 billion in 2019. Boundless is expected to make its Wall Street debut in the coming weeks after unveiling plans to go public earlier this month. Biotech tickers have traditionally stuck to letters that encompass their name, like RayzeBio’s RYZB. Others rely on their chosen modality, like Moderna’s MRNA. And some go the route of the technology they’re deploying — like Editas Medicine’s EDIT for gene editing, while four-letter names often beget four-letter symbols, like JAZZ. Joshua Pinto “You want to make it unique to the company so it’s really like a branding event,” Neumora CFO Joshua Pinto said in an interview. “Second, you want to make it easy to remember.” Neumora, a Phase III neuroscience biotech, went public in September as NMRA. In its early days, the ARCH Venture Partners startup went by the nickname of “Really Big Neuroscience Company.” “I won’t say what choice No. 2 or 3 was, but as you could imagine, we had some fun with some of the prior acronyms behind the company,” Pinto said. One recent entrant also took a playful approach. In its January IPO, Fractyl Health, a Massachusetts biotech working on cardiometabolic medicines, went with GUTS — a play on both gut health and bravery. “We’ve been talking about intestinal fortitude from the perspective of the tenacity and commitment and conviction required to be successful,” Fractyl CEO Harith Rajagopalan said in an interview, “but then also intestinal fortitude, as something that is impaired in people with obesity and metabolic disease.” Harith Rajagopalan On the day of its IPO, Fractyl gave its employees T-shirts with the phrase, “No guts, no glory.” The biotech plans to start testing its GLP-1 gene therapy in humans as a potential type 2 diabetes treatment in the first half of next year. “The greatest ticker symbol of all time was Genentech’s use of DNA back in the day,” Rajagopalan said. “You think, ‘Well, what are we trying to convey with this ticker symbol about who we are, about what we do, about the way in which we do it?’ GUTS was just too good to pass up on.” DNA is now the ticker for Ginkgo Bioworks, a synthetic biology company that has seen its valuation crater since going public in 2021. As more biotechs go public, they’ll have to be creative with their ticker symbols to stand out in what may be an increasingly crowded field — and many obvious choices are… #lucidquest #genetherapy #celltherapy

Selecting the right automation technology is crucial for streamlining workflows and maximizing efficiency. The team at Totus Medicines valued the versatility of our firefly #liquidhandling platform, which meant it could be used to automate not only #DELscreening workflows, but also technology development projects and #NGS library preparation. Learn more about the team's transition to automated liquid handling, and how it has supported their efforts in small molecule #drugdiscovery: https://bit.ly/44DBN8M

A reacquisition of Grail would require two developments, the first of which is a changing of the guard at the US Federal Trade Commission. This could follow a change in the occupant of the Oval Office, although I would point out that an election is also pending in the European Union, which also scotched the Illumina-Grail deal. The second main ingredient is more competition for multi-cancer early detection (MCED) tests, which is taking shape in the US despite a lack of Medicare coverage. At least some analysts seem a bit blase about the market prospects for MCEDs in the absence of coverage for those at average risk for cancer, but the sheer cost of modern cancer therapies might eventually torque that conversation in favor of population-level screening for a wide range of cancers.

Thoughts on this? >> J&J’s dealmaker: Plenty of ‘firepower,’ but mostly focused on tuck-in M&A >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #productmarketing #healthcare

PRISM MarketView highlights Oncocyte Corporation's (Nasdaq:OCX) recent inclusion in the Russell Microcap® Index, boosting its visibility among investors. This marks a key moment as Oncocyte continues to pioneer in molecular diagnostics. https://bit.ly/3RNNMuX #stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismDigitalMedia #PrismMediaWire

It’s no secret that the digital therapeutics market went a bit pear-shaped in 2023 - forcing key players to rethink what a successful DTx business model looks like. Take Freespira, for example. The developers of a software- and device-based treatment for panic and post-traumatic stress disorders are gradually working towards profitability, a few thousand users at a time - and it looks like the strategy is paying off. SomX’s Jessica Somauroo delved into the current investment landscape and highlighted that the high expectations placed on early-stage companies and investors are contributing to the existing friction in the market ⬇️ #digitalhealth #healthechpigeon #digitalcommunication